With 360° rotation, the 6-position pipette work station, TwisterTM universal 336, enables quick and easy instrument selection. Storage space is provided for six pipettes of most brands, and the interchangeable discs are available in a choice of seven translucent colours. The unit is simple to disassemble and reassemble for cleaning.
Read more
Processing pathogen panels in seconds, the autoSCAN-4 system simplifies identification and antibiotic suceptibility testing while standardising results. It can be used as an excellent supplemental system for difficult organisms or as a primary instrument for low volume usage. The system includes LabPro Information Management software designed to simplify workflow and minimise technologist interaction while accommodating differing regional and institutional environments through extensive customisation features. The optional LabPro AlertEX software eliminates manual review for unusual conditions or results and integrates institution-specific resolution guidance into the workflow. Panels include conventional panels with direct, non-ID-dependant Minimal Inhibitory Concentrations (MICs), to help zero in on emerging resistance, and speciality ID panels for reduced TAT when speed is critical.
Read more
This newly released portfolio of immunoassay surfaces ensures that users get the best results from their assays. Passive binding surfaces are available to absorb medium to large biomolecules in a range of orientations. For more specific binding, the Nunc CovaLink plates facilitate coupling of molecules bearing a free carboxyl or phosphate group, enabling peptides, haptens and DNA to be effectively coupled. In addition, the Immobilizer amino plate forms stable covalent bonds with the free amino acids or sulphhydryl groups of the biomolecule, eliminating the need for a blocking step. Affinity capture surfaces offer even more specific binding, with reduced variability in molecular orientation and improved signal to noise ratio. In order to help users to select the best plate format to meet the demands of their application, the interactive and searchable immunoassay plate selector guide is a free resource, providing in-depth detail about the range of plates available and their applications.
Read more
It has been estimated that 3 to 4 million people are infected with hepatitis C virus (HCV) each year. Four out of five people develop chronic hepatitis C infection, which can subsequently lead to liver cirrhosis and/or liver cancer. Early detection is the key to combating hepatitis; hepatitis C infection can be effectively controlled or treated if it is diagnosed early. HCV ELISA and rapid tests are widely used for screening and diagnosis of hepatitis C infection. These tests use specific antigens from the structural region and non-structural regions of the virus to detect the presence of antibodies to HCV. Reactive samples from screening tests are then confirmed by immunoblot assay. The MULTISURE HCV Antibody Assay is a qualitative immunochromatographic assay, intended for the detection of antibodies specific to HCV core, NS3, NS4 and NS5 antigens. The test is based on the capture of HCV antibodies using immobilised HCV recombinant antigens on a nitrocellulose membrane and the subsequent detection of captured analyte using goat anti-human IgG conjugated to colloidal gold. It has been developed from the patented reverse-flow test platform, giving greater sensitivity and easy-to-read visual signals. Similar to a confirmatory immunoblot, this assay can detect and differentiate the structural and non-structural HCV proteins. The test result pattern may, therefore, offer information such as the possible phase of the Hepatitis C infection. This simple and rapid assay takes only 15 minutes and is easy to use. It is an instrument-free platform and does not require highly trained personnel to perform the test, thus making it suitable for use in a point-of-care setting. With shortened turnaround time, patients are diagnosed early and have wider access to treatment and care.
A lactate assay is now available for Siemens’ recently launched RAPIDPoint 500 system for cartridge-based critical care testing at the point of care. Lactate joins an already extensive assay menu that includes blood gas, electrolytes, metabolites and CO-oximetry. The user-friendly system delivers rapid and accurate test results in approximately 60 seconds. The lactate assay further enhances the system’s functionality for clinicians relying on critical-care testing in, for example, Accident & Emergency departments or Intensive Care Units.
Read more
Cryptosporidiosis is routinely diagnosed by microscopic analysis of stool samples using organic dyes, or by immunostaining with direct fluorescent antibody, and it can be difficult to detect. Similarly, Giardia lamblia infection is frequently misdiagnosed, relying on poorly performing antigen-based testing. A new enzyme immunoassay (EIA) for the qualitative detection of Cryptosporidium and G. lamblia antigens in human faecal specimens from patients displaying gastrointestinal symptoms, the Prolisa Cryptosporidium/Giardia EIA kit offers precise results with high sensitivity and excellent specificity, enabling accurate diagnosis of infection. This convenient, rapid and easy-to-use method of detecting Cryptosporidium and G. lamblia is supplied in a 96-well test size consisting of detachable stripwells. This assay uses monoclonal anti-Cryptosporidium and anti-G. lamblia antibodies to ensure excellent sensitivity and specificity for high value diagnostic results. It can be performed manually as well as on most automated platforms for increased workflow flexibility.
Read more
The Randox Acusera Liquid Chemistry Premium Plus control is the most comprehensive serum chemistry control available covering over 100 parameters. Our extensive analyte menu includes a wide range of routine chemistries, immunoassays, lipids, cardiac markers, proteins, therapeutic drugs, trace metals and electrophoresis allowing for effective consolidation and significant cost savings.
Providing high lot-to-lot consistency and quality the MagNA Pure 96 System for automated sample preparation is able to purify a broad spectrum of human samples and offers LIMS (laboratory information management system) connectivity for safer and more convenient data transfer. It provides ready-to-use reagents and uses a minimal number of consumables for purification of nucleic acids from up to 96 clinical samples in less than 60 minutes. The instrument performance characteristics of MagNA Pure have been established in external trials with model parameters. This platform is ideal for clinical trials, medical research and molecular diagnostic testing that requires consistent high-quality sample analysis.
Read more
In addition to its already broad offering of clinical and research based products for the in vitro diagnostics and life sciences industries, Binding Site now offers human clinical specimens to both IVD manufacturers and suppliers. The availability and sourcing of high quality clinical specimens is vital in ensuring the scientific relevance and validity of clinical instrumentation and reagent applications. In addition, these specimens are also necessary for a host of other critical studies, including new product development work, validation studies and ongoing technical support projects. Compliant with all regulatory and quality standards guidelines, the clinical specimens can be provided in a variety of different matrices, which can be further characterised by specific analyte and concentration/titre, along with additional information on age, gender and disease state. Specimen volumes are available in a variety of configurations ranging from millilitres up to litre volumes, and are offered in a variety of formats (i.e. pooled sera/plasma, single donor, dialysed serum, etc.). All necessary documentation and paperwork is supplied with each shipment.
Read more
An evaluation to detect invasive Aspergillosis (IA) in a mixed population of 158 patients with underlying haematological or critical illness using the new commercial PCR test, the MycAssay, has been completed. The single-centre prospective evaluation tested the reliability and performance of the assay compared with clinical diagnosis and conventional diagnostic tests, such as culture and one of the current commercial gold-standards which is based around the detection of galactomannan (GM) in serum. The data generated from bronchoalveolar lavage [BAL] samples showed that the assay is a sensitive and specific molecular test for the diagnosis of IA which, in these early studies, appears to perform better than other assays in the study and is far superior to culture. Invasive aspergillosis is usually a hidden, clinical silent disease. Early detection of IA is critical for improved patient outcomes. Current tests are insensitive or suffer from false-positive and false-negative results. These new data are very promising in the context of haematological or critical illness and hopefully can be introduced into routine fungal disease guidelines at the earliest opportunity.
Read more
March 2026
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.